Sector News

Oxford BioMedica signs major supply deal with Novartis

July 7, 2017
Life sciences

Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.

The agreement builds on the collaboration announced between the group and Novartis in October 2014 and anticipates the commercial launch of CTL019 later this year for the blood cancer B-cell acute lymphoblastic leukaemia.

The deal could see Oxford BioMedica bank in excess of $100 million from Novartis over the next three years, including a $10 million upfront payment, various performance incentives and bioprocessing and development services.

In addition the UK group will also receive undisclosed royalties on potential future sales of Novartis’s CAR-T products.

Initially the supply agreement will run for three years, but this could be extended to five years subject to the wishes of both parties.

The deal, says Oxford BioMedica’s chief executive John Dawson, “demonstrates the value of our LentiVector platform and the quality of work we have delivered to Novartis over the last few years.

“The new deal with Novartis will strengthen the Group’s balance sheet immediately and will support the Group’s continued growth over the next three years.”

CAR-T offers a new treatment approach in that it is specifically manufactured for each individual patient. During the process, T cells are drawn from a patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient’s cancer cells and other B-cells expressing a particular antigen.

Novartis picked up rights to CTL019 under an agreement with the University of Pennsylvania in 2012, which also gives it worldwide rights to CARTs developed in all cancer indications.

By Selina McKee

Source: Pharma Times

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend